Ranibizumab for age-related macular degeneration: A meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 3, 2014, Pages 234-239

  Jiang, S ^a   Park, C ^a   Barner, J C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

anti VEGF; as needed; bevacizumab; clinical trials; monthly

Indexed keywords

BEVACIZUMAB; PLACEBO; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; META ANALYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SYSTEMATIC REVIEW; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84899425682     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12146     Document Type: Review

References (28)

1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY,. Age-related macular degeneration. Lancet, 2012; 379: 1728-1738.
2. Congdon N, O'colmain B, Klaver C, et al,. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol, 2004; 122: 477-485.
3. Friedman DS, O'colmain B, Munoz B, et al,. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol, 2004; 122: 564-572.
4. Bressler NM, Age-related macular degeneration is the leading cause of blindness. JAMA, 2004; 291: 1900-1901.
5. Ferrara N, Damico L, Shams N, Lowman H, Kim R,. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina, 2006; 26: 859-870.
6. Dadgostar H, Ventura A, Chung JY, Sharma S, Kaiser PK,. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmol, 2009; 116: 1740-1747.
7. Mitchell P, Korobelnik JF, Lanzetta P, et al,. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Brtish J Ophthalmol, 2010; 94: 2-13.
8. Schmidt-Erfurth U, Eldem B, Guymer R, et al,. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology, 2011; 118: 831-839.
9. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC,. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology, 2012; 119: 1399-1411.
10. Martin DF, Maguire MG, Fine SL, et al,. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology, 2012; 119: 1388-1398.
11. Martin D, Maguire M, Ying G, Grunwald J, Fine S, Jaffe G, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Eng J Med, 2011; 364: 1897-1908.
12. Subramanian ML, Abedi G, Ness S, et al,. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond), 2010; 24: 1708-1715.
13. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, Sinha S,. Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol, 2011; 59: 191-196.
14. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T,. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology, 2009; 116: 57-65.
15. Rosenfeld PJ, Brown DM, Heier JS, et al,. Ranibizumab for neovascular age-related macular degeneration. N Eng J Med, 2006; 355: 1419-1431.
16. Abraham P, Yue H, Wilson L,. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol, 2010; 150: 315-324.
17. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG,. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology, 2009; 116: 1731-1739.
18. Genetech. DME: clinical trials 2012; http://www.lucentis.com/hcp/dme/ clinical-trials-dme.html. Accessed 03/30, 2013.
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996; 17: 1-12.
20. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC,. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet, 2013; 382: 1258-1267.
21. Busbee BG, Ho AC, Brown DM, et al,. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology, 2013; 120: 1046-1056.
22. AAO. Preferred practice patterns: age-related macular degeneration: American Academy of Ophthalmology 2008. Available from: http://one.aao.org/CE/ PracticeGuidelines/PPP-Content.aspx?cid=f413917a-8623-4746-b441-f817265eafb4
23. NHS. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: National Institue for Health and Clinical Excellence 2008. Available from: http://www.nice.org.uk/TA155.
24. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol, 1982; 100: 912-918.
25. Bressler NM,. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arc Ophthalmol, 2001; 119: 198-207.
26. Antoszyk AN, Tuomi L, Chung CY, Singh A,. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol, 2008; 145: 862-874.
27. Kaiser PK, Boyer DS, Garcia R, et al,. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology, 2009; 116: 747-755.
28. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK,. A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: off-Label versus Goldstandard. PLoS ONE, 2012; 7: e42701.